<DOC>
	<DOCNO>NCT02409368</DOCNO>
	<brief_summary>The purpose study determine occurrence high-grade ( CTCAE v4.0 Grades 3-4 ) , treatment-related , select adverse event patient advance metastatic Squamous Cell Non-Small Cell Lung Cancer ( SqNSCLC ) progression disease least 1 systemic therapy .</brief_summary>
	<brief_title>An Open-Label , Multicenter Clinical Trial With Nivolumab ( BMS-936558 ) Monotherapy Subjects With Advanced Metastatic Squamous Cell ( Sq ) Non-Small Cell Lung Cancer ( NSCLC ) Who Have Received Least One Prior Systemic Regimen Treatment Stage IIIb/IV SqNSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com ECOG Status : PS 01 &amp; PS 2 Subjects histologically cytologicallydocumented SqNSCLC Subjects must experience disease progression recurrence one prior platinum doubletbased chemotherapy regimen Subjects must evaluable disease CT MRI per RECIST 1.1 criterion Subjects treat asymptomatic CNS metastases Prior palliative radiotherapy must complete least 14 day prior study drug administration Prior line antineoplastic therapy , include hemotherapy , hormonal therapy , immunotherapy , surgical resection lesion , nonpalliative radiation therapy , standard investigational agent treatment NSCLC , must complete 28 day prior first dose nivolumab Males Females , age 18 old Subjects untreated , symptomatic CNS metastases Subjects carcinomatous meningitis Subjects active , know suspected autoimmune disease . Subjects receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) previously take part randomize BMS clinical trial nivolumab ipilimumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>